Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Ram Vaidhyanath

Neuroradiology

View

Dr. Judith Gadde

Neuroradiology · Lurie Children's Hospital

View

Dr. Wende Gibbs

Neuroradiology · Barrow Neurological Institute

View

Dr. Daniel Gewolb

Neuroradiology · University of Miami

View

Dr. Sumir Patel

Neuroradiology · Emory University

View

Dr. Julie Bulman

Interventional Radiology · BIDMC

View

Dr. Monica Sheth

Breast Imaging · NYU Langone

View

Dr. Victoria Chernyak

Abdominal Imaging · CUIMC

View

Dr. Laura Hayes

Peds Radiology · Children's Healthcare of Atlanta

View

Dr. Amy Patel

Breast Imaging · UKHS

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Posttreatment FLAIR Hyperintense Vessels Refine mTICI-Based Reperfusion Phenotypes After Endovascular Thrombectomy.

    Aug 11, 2026DOI: 10.3174/ajnr.a9584Journal ArticleAJNR

    Written by: Derek A TsangMona GadKarthik LalwaniTobenna UbachukwuHamza A SalimDhairya A LakhaniNathan LuAakanksha SriwastwaVivek S Yedavalli

    Find these authors on Roon

    MG
    Dr. Mona Gad
    Neuroradiology

    Summary

    BACKGROUND AND PURPOSE: The modified Thrombolysis in Cerebral Infarction (mTICI) scale is the standard angiographic measure of reperfusion after endovascular thrombectomy (EVT), but outcomes remain heterogeneous even after successful mTICI 2b-3 reperfusion. We evaluated whether posttreatment FLAIR hyperintense vessels (FHV) refine mTICI-based reperfusion phenotypes and identify patients with worse 90-day functional outcome after EVT for ICA, M1, or M2 occlusions.MATERIALS AND METHODS: This retrospective cohort study included patients with acute ischemic stroke due to ICA, M1, or M2 occlusion treated with EVT who had available final mTICI grade, posttreatment FLAIR assessment, and valid 90-day modified Rankin Scale (mRS). Successful angiographic reperfusion was defined as mTICI 2b-3. FHV status was dichotomized as FHV-, defined as NIH-FHV score 0, versus FHV+, defined as NIH-FHV score >0. Patients were categorized into four mTICI/FHV phenotypes. The primary outcome was favorable 90-day functional outcome, defined as mRS 0-2. Multivariable logistic regression was performed among patients with mTICI 2b-3 reperfusion, with FHV analyzed both dichotomously and per 1-point increase in NIH-FHV score.RESULTS: A total of 205 patients were included: 132 had mTICI 2b-3/FHV-, 49 had mTICI 2b-3/FHV+, 8 had mTICI <2b/FHV-, and 16 had mTICI <2b/FHV+. Favorable 90-day outcome differed across phenotypes (p=.001). Among patients with mTICI 2b-3 reperfusion, favorable outcome occurred in 84/132 patients with FHV- (63.6%) versus 21/49 with FHV+ (42.9%). Persistent FHV was associated with lower adjusted odds of favorable outcome (adjusted OR, 0.26; 95% CI, 0.11-0.57; p<.001), and each 1-point increase in NIH-FHV score was similarly associated with lower odds (adjusted OR, 0.62; 95% CI, 0.45-0.83; p=.002).CONCLUSIONS: Posttreatment FHV refined mTICI-based reperfusion phenotyping after ICA/M1/M2 EVT. Among patients with mTICI 2b-3 reperfusion, persistent FHV identified a clinically discordant phenotype associated with lower rates of favorable 90-day functional outcome.
    MGDr. Mona Gad

    Dr. Mona Gad

    Radiology · Neuroradiology
    monag